Riskpilot← Back to searchSign inGet full accessSenzaGen AB
ABActiveOrg 5568219207Scheelevägen 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 201032 employees
Revenue 2024
SEK 38,8M
+53% vs 2023
EBITDA margin
-19.7%
+55% vs 2023
Equity ratio
89.5%
Financial strength
Net profit 2024
SEK -5,9M
+64% vs 2023
| Revenue | SEK 38,8M | +53% |
| EBITDA | SEK -7,7M | +55% |
| Net profit | SEK -5,9M | +64% |
| Total assets | SEK 115,9M | +26% |
| Equity | SEK 103,7M | +39% |
| Employees | 32 | — |
Legal name
SenzaGen AB
Org number
5568219207
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25 oktober 2010
Share capital
SEK 1 475 000
Employees
32 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av ledamöterna i förening med Borrebaeck, Karl Arne Krister Firman tecknas i förening av Borrebaeck, Karl Arne Krister Nählstedt, Bengt Peter Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet ska vara att bedriva medicinsk forskning, utveckling, undervisning och konsultverksamhet inom området diagnostik, till exempel test av kemikalier och allergener, samt som moderbolag leda och administrera sådan verksamhet samt förvalta fast och lös egendom och med ovanstående därmed förenlig verksamhet.
Address
Scheelevägen 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 958 | 12 164 | 21 501 | 25 350 | 38 796 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −27 198 | −31 339 | −21 596 | −16 928 | −7 650 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | −27 198 | −31 339 | −21 596 | −16 928 | −7 650 |
| Net financials | −206 | 190 | 239 | 384 | 1 786 |
| Profit before tax | −27 257 | −31 149 | −21 357 | −16 348 | −5 864 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −27 257 | −31 149 | −21 357 | −16 348 | −5 864 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 112 328 | 122 715 | 108 074 | 91 772 | 115 876 |
| Equity | 108 179 | 110 513 | 90 744 | 74 396 | 103 701 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 149 | 12 202 | 17 330 | 17 376 | 12 175 |
| Total debt | 4 149 | 12 202 | 17 330 | 17 376 | 12 175 |
EBITDA margin
-19.7%
This company
15.8%
Market median
-225% vs market
20202024
Equity ratio
89.5%
This company
38.2%
Market median
+134% vs market
20202024
Return on equity
-5.7%
This company
18.4%
Market median
-131% vs market
20202024
Net profit margin
-15.1%
This company
8.1%
Market median
-286% vs market
20202024
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
ML | Audit | 2021 |
UM Auditor Substitute | Auditor Substitute | 2020 |
BP Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
AE Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SenzaGen AB (this company)
SENZAGEN INCTOXHUB S.R.L.VITROSCREEN S.R.L.Senzagen IncVitroscreen S.R.L.Toxhub S.R.L.Board members of SenzaGen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats-Åke Lennart Andersson | Audit | 0 companies |
| Ulf Martin Ingvar Gustafsson | Auditor Substitute | 0 companies |
| Axel Erland Sjöblad | Chief Executive Officer | 0 companies |
| Bengt Peter Nählstedt | Chief Executive Officer | 0 companies |
| Paul Antony Yanni | Board of Directors | 0 companies |
| Ian Kimber | Board of Directors | 0 companies |
| Cecilia Ann-Christin Malmborg Hager | Board of Directors | 0 companies |
| Ann Ulrika Gidner | Board of Directors | 0 companies |
| Laura Cristina Chirica | Board of Directors | 0 companies |
| Karl Arne Krister Borrebaeck | Chairman | 0 companies |
| Lisa Paula Zeilon | Board of Directors | 0 companies |